Algert Global LLC Corvus Pharmaceuticals, Inc. Transaction History

Algert Global LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 14, 2022	SELL	$2.34 - $5.31 $34,980 - $79,379	-14,949 Closed	0 $0
Q3 2021 Nov 15, 2021	SELL	$1.89 - $8.53 $9,049 - $40,841	-4,788 Reduced 24.26%	14,949 $72,000
Q2 2021 Aug 13, 2021	SELL	$2.46 - $3.14 $56,875 - $72,596	-23,120 Reduced 53.95%	19,737 $53,000
Q1 2021 May 14, 2021	BUY	$2.86 - $4.77 $78,335 - $130,650	27,390 Added 177.09%	42,857 $132,000
Q4 2020 Feb 12, 2021	BUY	$3.56 - $4.86 $15,023 - $20,509	4,220 Added 37.52%	15,467 $55,000
Q3 2020 Nov 16, 2020	BUY	$2.6 - $5.37 $29,242 - $60,396	11,247 New	11,247 $45,000
Q2 2020 Aug 12, 2020	SELL	$2.01 - $4.05 $34,063 - $68,635	-16,947 Closed	0 $0
Q1 2020 May 13, 2020	BUY	$1.74 - $5.98 $29,487 - $101,343	16,947 New	16,947 $36,000

30.4M

1.06M

84.3K

Ticker CRVS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,553,500
Market Cap $223M
Description
Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, which is in Phase Ib/II clinical trial for non-small cell lung cancer and head and neck cancers. The compan...

Get notified when there are updates to the investment portfolio of Algert Global LLC, based on Form 13F filings with the SEC.

Stay updated on Algert Global LLC with notifications on news.